PE20091167A1 - Derivados heterociclicos con actividad sobre los receptores de ampa - Google Patents

Derivados heterociclicos con actividad sobre los receptores de ampa

Info

Publication number
PE20091167A1
PE20091167A1 PE2008001915A PE2008001915A PE20091167A1 PE 20091167 A1 PE20091167 A1 PE 20091167A1 PE 2008001915 A PE2008001915 A PE 2008001915A PE 2008001915 A PE2008001915 A PE 2008001915A PE 20091167 A1 PE20091167 A1 PE 20091167A1
Authority
PE
Peru
Prior art keywords
alkyl
methyl
cycloalkyl
activity
pyrimidin
Prior art date
Application number
PE2008001915A
Other languages
English (en)
Inventor
Craig Jamieson
Michael Gerard Gallagher
Amanda Jane Lyons
John Kinnaird Ferguson Maclean
Elizabeth Margaret Moir
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of PE20091167A1 publication Critical patent/PE20091167A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

REFERIDA A UN DERIVADO HETEROCICLICO DE FORMULA (I), DONDE L ES (CH2)m; R1 ES ALQUILO C1-C4, CICLOALQUILO C3-C5, ALQUILOXI C1-C4, HALOGENO, CN, ENTRE OTROS; R2 ES ALQUILO C1-C4, CICLOALQUILO C3-C5, ALQUILOXI C1-C4, ENTRE OTROS; X1, X2 Y X3 SON N O CR3; R3 ES H O METILO; Y1 ES NR4 O CHR4; R4 ES H O ALQUILO C1-C4; Y2 ES N O CR5; R5 ES H, ALQUILO C1-C4, CICLOALQUILO C3-C8, ARILO C6-C10; m ES 1 O 2; R6 ES H, ALQUILO C1-C4, CICLOALQUILO C3-C5; Y3 ES O,S, NR7; R7 ES H O ALQUILO C1-C4; Y4 ES N O CR8; R8 ES H O ALQUILO C1-C4. SON COMPUESTOS PREFERIDOS: 6-METIL-2-((4-(TIAZOL-2-ILMETILAMINO)METIL)-3-(TRIFLUOROMETIL)-1H-PIRAZOL-1-IL)METIL)TIENO[2,3-d]PIRIMIDIN-4(3H)-ONA, 2-((4-(2-HIDROXIPROPAN-2-IL)-3-(TRIFLUOROMETIL)-1H-PIRAZOL-1-IL)METIL)-6-METILTIENOL[2,3-d]PIRIMIDIN-4(3H)-ONA, 2-((4-(2-HIDROXIETIL)-3-(TRIFLUOROMETIL)-1H-PIRAZOL-1-IL)METIL)-6-METILTIENO[2,3-d]PIRIMIDIN-4(3H)-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD SOBRE LOS RECEPTORES DE AMPA (ACIDO ALFA-AMINO-3-HIDROXI-5-METIL-4-ISOXAZOL-PROPIONICO) Y SON UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, DEPRESION, TRANSTORNOS DEL APRENDIZAJE, ENTRE OTROS
PE2008001915A 2007-11-13 2008-11-12 Derivados heterociclicos con actividad sobre los receptores de ampa PE20091167A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07120603 2007-11-13

Publications (1)

Publication Number Publication Date
PE20091167A1 true PE20091167A1 (es) 2009-08-03

Family

ID=39472607

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001915A PE20091167A1 (es) 2007-11-13 2008-11-12 Derivados heterociclicos con actividad sobre los receptores de ampa

Country Status (18)

Country Link
US (1) US8129397B2 (es)
EP (1) EP2209791B1 (es)
JP (1) JP5455130B2 (es)
KR (1) KR20100106370A (es)
CN (1) CN101855227B (es)
AR (1) AR069286A1 (es)
AU (1) AU2008322986B2 (es)
BR (1) BRPI0819202A2 (es)
CA (1) CA2703901C (es)
CL (1) CL2008003362A1 (es)
CO (1) CO6270365A2 (es)
EC (1) ECSP10010247A (es)
MX (1) MX2010004686A (es)
PE (1) PE20091167A1 (es)
RU (1) RU2010123895A (es)
TW (1) TW200934497A (es)
WO (1) WO2009062930A1 (es)
ZA (1) ZA201002580B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
US20170313719A1 (en) * 2014-11-18 2017-11-02 Emory University Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto
LT3386591T (lt) 2015-12-09 2020-10-12 Cadent Therapeutics, Inc. Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas
EP3386990B1 (en) 2015-12-09 2023-04-19 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
EP3558318B1 (en) 2016-12-22 2023-12-20 Novartis AG Nmda receptor modulators and uses thereof
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds
IL280474B2 (en) 2018-08-03 2023-09-01 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2541458C (en) * 2003-10-08 2011-09-20 Eli Lilly And Company Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
ES2383115T3 (es) 2004-01-09 2012-06-18 Eli Lilly And Company Compuestos de tiofeno y furano
AU2006227729B2 (en) * 2005-03-16 2011-10-13 Aventis Pharmaceuticals Inc. Dipyrazoles as central nervous system agents
GB0507298D0 (en) * 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US8293754B2 (en) * 2005-06-14 2012-10-23 Aska Pharmaceutical Co., Ltd. Thienopyrimidine derivatives
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives

Also Published As

Publication number Publication date
CA2703901C (en) 2016-05-10
US20090131455A1 (en) 2009-05-21
KR20100106370A (ko) 2010-10-01
WO2009062930A1 (en) 2009-05-22
JP5455130B2 (ja) 2014-03-26
JP2011503139A (ja) 2011-01-27
ECSP10010247A (es) 2010-07-30
MX2010004686A (es) 2010-05-19
CL2008003362A1 (es) 2009-06-26
TW200934497A (en) 2009-08-16
RU2010123895A (ru) 2011-12-20
US8129397B2 (en) 2012-03-06
AR069286A1 (es) 2010-01-13
CN101855227A (zh) 2010-10-06
BRPI0819202A2 (pt) 2015-05-05
EP2209791A1 (en) 2010-07-28
CN101855227B (zh) 2013-01-23
CO6270365A2 (es) 2011-04-20
EP2209791B1 (en) 2014-01-22
CA2703901A1 (en) 2009-05-22
AU2008322986B2 (en) 2013-08-01
AU2008322986A1 (en) 2009-05-22
ZA201002580B (en) 2010-12-29

Similar Documents

Publication Publication Date Title
PE20091167A1 (es) Derivados heterociclicos con actividad sobre los receptores de ampa
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20120120A1 (es) DERIVADOS DE 2H-PIRAZOLO[3,4-d]PIRIMIDINA-4,6(5H,7H)-DIONA, COMO INHIBIDORES DE PDE1
PE20081612A1 (es) Analogos de las pterinas
PE20140390A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20070021A1 (es) Compuestos triazolopiridinas como antagonistas de receptor canabinoide 1
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
PE20180500A1 (es) Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20141582A1 (es) Pirimidinas anilladas sustituidas y uso de las mismas
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
PE20170189A1 (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20091056A1 (es) PIRIDO[3,2-e]PIRAZINAS, SU PROCEDIMIENTO DE PREPARACION Y USO COMO INHIBIDORES DE FOSFODIESTERASA 10
PE20120418A1 (es) DERIVADOS DE PIRIDO[2,3-b]PIRAZINA COMO INHIBIDORES DE POLI (ADP-RIBOSA) POLIMERASA (PARP)
PE20110944A1 (es) DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1
NZ599815A (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
PE20141540A1 (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
PE20090773A1 (es) Derivados de morfolina pirimidina
UY32391A (es) Compuestos amino-heterocíclicos
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
PE20131100A1 (es) Combinacion del compuesto glyt1 con antipsicoticos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed